2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
186
HER2-positive Breast Cancer
18
Neoplasms
13
Neoplasm Metastasis
11
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Colonic Neoplasms
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Hematologic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Solid Tumor
3
Rectal Neoplasms
3
Pathologic Complete Response
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
HER2-positive Early Breast Cancer
3
Esophageal Neoplasms
3
Breast Neoplasms, Male
3
Biliary Tract Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Locally Advanced Breast Cancer
2
Interventions
Echocardiography
4
sacubitril and valsartan sodium hydrate drug combination
3
Standard of Care
3
Nutrition Assessment
3
Exercise
3
Electrocardiography
3
Carvedilol
3
dapagliflozin
2
Surveys and Questionnaires
2
Spironolactone
2
Rituximab
2
Lenalidomide
2
Ivabradine
2
Control Groups
2
Blood Specimen Collection
2
Atorvastatin
2
Adrenergic beta-Antagonists
2
ziprasidone
1
pertuzumab
1
pegfilgrastim
1
obinutuzumab
1
nicotinamide-beta-riboside
1
empagliflozin
1
candesartan
1
acalabrutinib
1
Zolpidem
1
Watchful Waiting
1
Warfarin
1
Vincristine
1
Vecuronium Bromide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Heart Failure
×
pertuzumab
×
Clear all
NCT04680442
2025-04-06
SCHOLAR-2
Population Health Research Institute
Phase 2
Recruiting
130 enrolled